Floatz logo

Everolimus

B-cell Adult Acute Lymphoblastic Leukemia

Mayo ClinicSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the B-cell Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
Mayo Clinic
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →